M&A Deal Summary

Arcutis Acquires Ducentis BioTherapeutics

On September 7, 2022, Arcutis acquired life science company Ducentis BioTherapeutics for 16M USD

Acquisition Highlights
  • This is Arcutis’ 1st transaction in the Life Science sector.
  • This is Arcutis’ largest (disclosed) transaction.
  • This is Arcutis’ 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2022-09-07
Target Ducentis BioTherapeutics
Sector Life Science
Buyer(s) Arcutis
Deal Type Add-on Acquisition
Deal Value 16M USD
Advisor(s) Goodwin Procter (Legal)

Target

Ducentis BioTherapeutics

Oxfordshire, United Kingdom
Ducentis BioTherapeutics is a pre-clinical stage biotech company aiming to develop novel therapies for autoimmune disease patients with poor treatment options. Ducentis BioTherapeutics was founded in 2015 and is based in Oxfordshire, United Kingdom.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Arcutis

Westlake Village, California, United States
Category Company
Founded 2016
Sector Life Science
Employees296
Revenue 60M USD (2023)
DESCRIPTION

Arcutis is focused on developing topical medicines for the treatment of skin diseases. The company’s lead program, ARQ-151, is a topical formulation of roflumilast that is currently in Phase 2 studies for the treatment of plaque psoriasis and atopic dermatitis. The company’s second program, ARQ-250, is a topical JAK1-inhibitor in preclinical development for the treatment of various autoimmune diseases affecting the skin. Arcutis was founded in 2016 and is based in Westlake Village, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United Kingdom) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal